For the year ending 2025-12-31, RANI had $14,556K increase in cash & cash equivalents over the period. -$18,802K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -40,950 |
| Stock-based compensation expense | 11,798 |
| Depreciation and amortization | 900 |
| Net accretion and amortization of investments in marketable securities | 278 |
| Loss on disposal of property and equipment | 0 |
| Impairment loss | 0 |
| Non-cash operating lease expense | 1,908 |
| Amortization of debt discount and issuance costs | 207 |
| Loss on extinguishment of debt | -576 |
| Warrant issued for services provided | -152 |
| Modification expense related to warrants | 15 |
| Accounts receivable | 2,042 |
| Contract asset | -428 |
| Prepaid expenses and other current assets | 192 |
| Accounts payable | -1,050 |
| Accrued expenses and other current liabilities | 3,184 |
| Deferred revenue | 8,539 |
| Operating lease liabilities | -1,909 |
| Net cash used in operating activities | -18,714 |
| Proceeds from maturities of marketable securities | 26,750 |
| Purchases of marketable securities | 33,692 |
| Purchases of property and equipment | 88 |
| Net cash (used in) provided by investing activities | -7,030 |
| Proceeds from exercise of warrants issued-July Two Thousand Twenty Four And October Two Thousand Twenty Four Securities Purchase Agreement | 3,869 |
| Proceeds from issuance of common stock-October Securities Purchase Agreement | 0 |
| Proceeds from issuance of common stock-July Two Thousand Twenty Five Securities Purchase Agreement | 2,811 |
| Proceeds from issuance of common stock-July Securities Purchase Agreement | 0 |
| Issuance of common stock under employee stock purchase plan | 61 |
| Proceeds from employee stock purchase plan | 12 |
| Proceeds from issuance of common stock-Private Placement Securities Purchase Agreement | 49,788 |
| Proceeds from exercise of series d warrants | 4,530 |
| Proceeds from exercise of stock options | 10 |
| Tax withholdings paid on behalf of employees for net share settlement | 59 |
| Repayment of debt | 20,722 |
| Net cash provided by financing activities | 40,300 |
| Net increase (decrease) in cash, cash equivalents and restricted cash equivalents | 14,556 |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | 4,262 |
| Cash, cash equivalents and restricted cash equivalents, end of period | 18,818 |
Rani Therapeutics Holdings, Inc. (RANI)
Rani Therapeutics Holdings, Inc. (RANI)